A detailed history of Buckingham Strategic Partners transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 210 shares of REGN stock, worth $217,188. This represents 0.01% of its overall portfolio holdings.

Number of Shares
210
Holding current value
$217,188
% of portfolio
0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$902.69 - $993.35 $189,564 - $208,603
210 New
210 $202,000
Q3 2022

Nov 14, 2022

BUY
$573.97 - $724.32 $258,860 - $326,668
451 New
451 $311,000
Q1 2022

May 10, 2022

SELL
$595.12 - $698.43 $203,531 - $238,863
-342 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$543.48 - $670.97 $185,870 - $229,471
342 New
342 $216,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $111B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Buckingham Strategic Partners Portfolio

Follow Buckingham Strategic Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.